Senior Level Meetings Included Discussion of Tivic's TLR5 and Vagus Nerve Stimulation Programs Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th. The U.S. Government, through agencies including BARDA, NASA, Defense Threats Reduction Agency, Department of the Army, and the Department of Defense, has previously provided significant funding to the development of Tivic's TL

Tivic Health Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell essential for combating infections. Causes of neutropenia include chemotherapy and radiation treatments, chronic infection, autoimmune diseases, bone marrow disorde

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health's common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol "TIVC." About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health's bioelectronic division is developing non-invasive medical devices that personalize key stimulation parameters f

Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. "The important strategic events of the past several months have been nothing short of transformative," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "We have successfully reshaped the company by expanding Tivic's opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID Code: 13752399 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonom

Advances Tivic's Development of Non-Invasive VNS Devices Aimed at Treating Inflammatory, Cardiac and Neurologic Disorders Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to current, more invasive treatment options. The data were presented in a poster presentation, titled, "Autonomic,

Tivic Health® Systems, Inc. (NASDAQ:TIVC) ("Tivic Health" or the "Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq"), and is part of the Company's Compliance Plan, as presented to Nasdaq on February 18, 2025. The reverse stock split was approved by the stockholders of the Company at a special meeting of the Company held on January 31, 2025. The reverse stock split will

- Patent based on state-of-the-art science of vagus nerve stimulation approach shows greater effect from personalization of treatment - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled "Method and Apparatus for Electrical Stimulation of the Vagus Nerve," expands the claims and protection around the technology in advance of potential U.S. Food & Drug Administration approval and commercialization of Tivic's non-invasive cervical vagus nerve sti

Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. "The important strategic events of the past several months have been nothing short of transformative," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "We have successfully reshaped the company by expanding Tivic's opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID Code: 13752399 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonom

Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. "This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," stated Jennifer Ernst, CEO of Tivic Health. "The first prong is the aggressive steps we have taken to improve the economics of the ClearUP product line -- our comme

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be submitted to [email protected] by November 11. Conference Call Details: Toll Free: 877-545-0523 International: 973-528-0016 Access Code: 507355 Webcast Link

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to [email protected] by August 11, 2024. Teleconference Details:

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 464810 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50489 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures

Tivic Health® Systems, Inc. ("Tivic Health") (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 434944 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50026 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus

71% Gross Profit Increase; 30% Decrease in Operating Expenses Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 ("Q3 2023"). Third Quarter 2023 Financial Highlights Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. Gross Margin of 38% in Q3 2023, compared to 13% in Q3 2022. Total operating expenses for Q3 2023 was $1.9 million, compared to $2.6 million for Q3 2022, a d

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter 2023 via pre-recorded conference call and webcast on Tuesday, November 14th, 2023 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 302318 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/49228 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, an

Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib